Integra LifeSciences Holdings Corporation
IART · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 2.28 | -0.84 | 2.86 | 1.26 |
| FCF Yield | 1.43% | 2.15% | 4.67% | 4.66% |
| EV / EBITDA | 18.03 | 17.55 | 14.86 | 18.59 |
| Quality | ||||
| ROIC | 0.29% | 2.66% | 5.55% | 4.42% |
| Gross Margin | 54.77% | 57.63% | 62.29% | 61.24% |
| Cash Conversion Ratio | -18.63 | 2.07 | 1.46 | 1.85 |
| Growth | ||||
| Revenue 3-Year CAGR | 1.12% | -0.02% | 4.32% | 0.54% |
| Free Cash Flow Growth | -65.84% | -66.38% | -17.77% | 88.90% |
| Safety | ||||
| Net Debt / EBITDA | 8.99 | 5.13 | 2.96 | 3.11 |
| Interest Coverage | 0.40 | 2.17 | 4.82 | 3.91 |
| Efficiency | ||||
| Inventory Turnover | 1.70 | 1.68 | 1.81 | 1.88 |
| Cash Conversion Cycle | 235.39 | 227.52 | 199.99 | 210.89 |